Skip to main content

Advertisement

Table 3 Statistical analysis of delta changes of fatty acids, amino acids and activin/follistatins in liraglutide- and placebo-treated individuals

From: Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

Fatty acids Placebo Liraglutide P1 P2 P3 P4
Visit 1 Visit 6 Delta changes Visit 1 Visit 6 Delta changes
TotFA 9.04 ± 2.01 9.47 ± 2.1 0.44 ± 0.25 8.65 ± 1.94 8.5 ± 1.9 − 0.16 ± 0.2 0.07 0.07   
UnSat (× 102) 110 ± 24.6 112 ± 25 1.73 ± 0.84 110 ± 24.7 112 ± 25 1.22 ± 0.91 0.64 0.74   
DHA (× 102) 8.7 ± 1.93 10 ± 2.21 1.75 ± 0.85 9.07 ± 2.03 8.77 ± 1.96 − 0.3 ± 0.46 0.04 0.09   
LA 2.5 ± 0.55 2.65 ± 0.59 0.15 ± 0.06 2.39 ± 0.54 2.38 ± 0.53 − 0.02 ± 0.08 0.07 0.1   
FAw3 0.28 ± 0.06 0.31 ± 0.07 0.04 ± 0.01 0.27 ± 0.06 0.27 ± 0.06 0.002 ± 0.02 0.04 0.11   
FAw6 3.02 ± 0.67 3.18 ± 0.71 0.16 ± 0.07 2.92 ± 0.65 2.87 ± 0.64 − 0.05 ± 0.08 0.03 0.04   
PUFA 3.3 ± 0.73 3.5 ± 0.78 0.2 ± 0.08 3.19 ± 0.71 3.14 ± 0.7 − 0.05 ± 0.1 0.03 0.05   
MUFA 2.27 ± 0.51 2.36 ± 0.52 0.09 ± 0.08 2.21 ± 0.49 2.17 ± 0.49 − 0.04 ± 0.06 0.23 0.15   
SFA 3.41 ± 0.76 3.53 ± 0.78 0.12 ± 0.1 3.25 ± 0.73 3.18 ± 0.71 − 0.07 ± 0.06 0.12 0.1   
C22:0 0.15 ± 0.01 0.14 ± 0.01 − 0.01 ± 0.01 0.14 ± 0.01 0.17 ± 0.01 0.02 ± 0.01 0.02 0.03   
Amino acids           
 Tyrosine (× 102) 6.15 ± 1.38 6.46 ± 1.44 0.31 ± 0.26 6.48 ± 1.45 5.77 ± 1.29 − 0.71 ± 0.25 0.03 0.001   
ELISAs           
 Follistatin 3.43 ± 0.26 3.62 ± 0.25 0.01 ± 0.16 3.51 ± 0.32 2.7 ± 0.26 − 0.95 ± 0.24 0.007 0.004 0.02 0.81
 FSTL3 12.5 ± 0.65 12.1 ± 0.48 − 1.03 ± 0.52 12.5 ± 0.68 12 ± 0.77 − 0.52 ± 0.6 0.52 0.31 0.67 0.88
 Activin A 0.43 ± 0.02 0.37 ± 0.03 − 0.08 ± 0.02 0.43 ± 0.03 0.3 ± 0.02 − 0.12 ± 0.02 0.13 0.85 0.17 0.9
 Activin B 96.6 ± 8.71 101 ± 8.5 4.51 ± 4.59 99.2 ± 10.2 109 ± 10.7 4.66 ± 3.27 0.98 0.95 0.72 0.65
 Activin AB 3.26 ± 0.38 3.76 ± 0.41 0.52 ± 0.2 3.57 ± 0.46 2.94 ± 0.42 − 0.63 ± 0.29 0.04 0.004 0.03 0.1
 Activin A/FST 0.14 ± 0.01 0.11 ± 0.01 − 0.03 ± 0.01 0.14 ± 0.01 0.13 ± 0.01 − 0.01 ± 0.01 0.26 0.03 0.33 0.52
 Activin B/FST 31.6 ± 3.57 30.8 ± 3.33 − 1.01 ± 2.03 30.5 ± 2.79 41.8 ± 4.31 10.3 ± 2.45 0.01 0.03 0.02 0.09
 ActivinAB/FST 1.21 ± 0.2 1.18 ± 0.15 − 0.03 ± 0.09 1.16 ± 0.17 1.24 ± 0.21 0.08 ± 0.13 0.43 0.54 0.46 0.13
  1. Values are given in mmol/L. P1—Delta statistics unadjusted. P2—Delta changes adjusted for changes in weight. P3—Delta changes adjusted for changes in glucose. P4—Delta changes adjusted for the change in HOMA-IR index. Values are reported as mean ± SE. On treatment analysis was performed for all variables. The level of significance was set to p-value < 0.05 after Bonferroni correction. Baseline samples collected at visit 1, post treatment samples were collected at visit 6 (5 weeks of treatment total)
  2. TotFA total fatty acids, UnSat unsaturated fatty acids, DHA 22:6, docosahexaenoic acid, LA 18:2, linoleic acid, FAw3 omega-3 fatty acids, FAw6 omega-6 fatty acids, PUFA polyunsaturated fatty acids, MUFA monounsaturated fatty acids, SFA saturated fatty acids, C22:0 behenic acid